Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Chemical substance: Ketoprofen
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Ketoprofen 2.5% gel
100302010AAAAAA
|
Ketoprofen (Topical) | Ketoprofen | Musculoskeletal and Joint Diseases | 35,064 |
|
Powergel 2.5% gel
100302010BCAAAA
|
Powergel | Ketoprofen | Musculoskeletal and Joint Diseases | 1,774 |
|
Ketoprofen 200mg modified-release capsules
1001010L0AAAJAJ
|
Ketoprofen (Systemic) | Ketoprofen | Musculoskeletal and Joint Diseases | 1,612 |
|
Ketoprofen 100mg modified-release capsules
1001010L0AAAIAI
|
Ketoprofen (Systemic) | Ketoprofen | Musculoskeletal and Joint Diseases | 1,113 |
|
Oruvail 200 modified-release capsules
1001010L0BDABAJ
|
Oruvail (Systemic) | Ketoprofen | Musculoskeletal and Joint Diseases | 288 |
|
Oruvail 2.5% gel
100302010BBAAAA
|
Oruvail (Topical) | Ketoprofen | Musculoskeletal and Joint Diseases | 161 |
|
Oruvail 100 modified-release capsules
1001010L0BDAAAI
|
Oruvail (Systemic) | Ketoprofen | Musculoskeletal and Joint Diseases | 135 |
|
Tiloket 2.5% gel
100302010BEAAAA
|
Tiloket (Topical) | Ketoprofen | Musculoskeletal and Joint Diseases | 66 |
|
Larafen CR 200mg capsules
1001010L0BHAAAJ
|
Larafen | Ketoprofen | Musculoskeletal and Joint Diseases | 3 |
|
Ketoprofen 100mg suppositories
1001010L0AAAPAP
|
Ketoprofen (Systemic) | Ketoprofen | Musculoskeletal and Joint Diseases | 1 |
|
Axorid 100mg/20mg modified-release capsules
1001010L0BQAAAM
|
Axorid | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Axorid 200mg/20mg modified-release capsules
1001010L0BQABAN
|
Axorid | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Fenoket 200mg modified-release capsules
1001010L0BJAAAJ
|
Fenoket | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Jomethid XL 200mg capsules
1001010L0BMAAAJ
|
Jomethid | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Ketocid 200 modified-release capsules
1001010L0BIAAAJ
|
Ketocid 200 | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Ketoprofen 10% gel
100302010AAACAC
|
Ketoprofen (Topical) | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Ketoprofen 100mg / Omeprazole 20mg modified-release capsules
1001010L0AAAMAM
|
Ketoprofen (Systemic) | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Ketoprofen 100mg capsules
1001010L0AAABAB
|
Ketoprofen (Systemic) | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Ketoprofen 100mg/2ml solution for injection ampoules
1001010L0AAAGAG
|
Ketoprofen (Systemic) | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Ketoprofen 150mg modified-release capsules
1001010L0AAALAL
|
Ketoprofen (Systemic) | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Ketoprofen 200mg / Omeprazole 20mg modified-release capsules
1001010L0AAANAN
|
Ketoprofen (Systemic) | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Ketoprofen 50mg capsules
1001010L0AAAAAA
|
Ketoprofen (Systemic) | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Ketotard XL 200mg capsules
1001010L0BLAAAJ
|
Ketotard | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Ketovail 100mg modified-release capsules
1001010L0BEAAAI
|
Ketovail | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Ketovail 200mg modified-release capsules
1001010L0BEABAJ
|
Ketovail | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.